drugset / Trial / NCT05654194
Azacitidine Combined With Venetoclax and ATRA in Newly Diagnosed AML
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm study to evaluate the safety and efficiency of azacitidine (AZA) combination with venetoclax and ATRA in Patients With Newly diagnosed acute myeloid leukemia. Azacitidine, venetoclax and ATRA, may stop the growth of cancer cells, either by demethylation, by promoting cells differentiation or by killing the cells.
Timeline
- Start
- 2022-10-31
- Primary completion
- 2024-09-29
- Completion
- 2026-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 70 mg/m2 | — |
| Subject | Tretinoin | Small molecule | 45 mg/m2 | — |
| Subject | Venetoclax | Small molecule | 400 mg | Oral |